The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Company ...

In terms of product development, Eli Lilly reported that its drug Omvoh has shown sustained efficacy in Crohn's disease patients over two years of continuous treatment. This promising development ...

We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take ...

INDIANAPOLIS—Lilly Endowment Inc., a major shareholder in Eli Lilly & Co. (NYSE:LLY), has recently sold a significant portion ...

and the approval of Omvoh for treating moderately to severely active Crohn’s disease. Eli Lilly and Company (NYSE:LLY) declared a 15.4% hike in its quarterly dividend in December 2024 to $1.50 ...

UPDATED: Thursday, Jan. 16 at 10:25 a.m. ET Eli Lilly's Omvoh has picked up its second major FDA nod. After the IL-23 inhibitor's approval in 2023 to treat ulcerative colitis, the agency has now ...